Were Neil Kumar’s BridgeBio (BBIO) share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were effected under a Rule 10b5-1 sales plan adopted on March 31, 2025. Such plans allow insiders to pre-schedule trades, helping separate their personal trading decisions from later, potentially material, information about the company.

How are trust-held BridgeBio (BBIO) shares related to Neil Kumar treated in this Form 4?

The filing shows shares held by the Kumar Haldea Revocable Trust and Kumar Haldea Family Irrevocable Trust, with Kumar as co-trustee. A footnote states he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, clarifying how Section 16 ownership is interpreted.

BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. Chief Executive Officer and director Neil Kumar reported open-market sales of 26,103 shares of common stock on May 21, 2026. The shares were sold at weighted average prices within ranges from $66.81 to $70.97 per share under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.

Following these transactions, Kumar directly holds 267,174 BridgeBio common shares. In addition, the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, for which he serves as co-trustee, hold 4,358,447 and 555,686 shares, respectively, although he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 26,103 shares ($1,812,522)

Net Sell 7 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 26,103 shs ($1.81M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,256	$67.5687	$152K
Sale	Common Stock	6,725	$68.3025	$459K
Sale	Common Stock	5,072	$69.2235	$351K
Sale	Common Stock	11,250	$70.4814	$793K
Sale	Common Stock	800	$70.9189	$57K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 267,174 shares (Direct, null); Common Stock — 555,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Key Figures

Shares sold: 26,103 shares Sale price range (footnotes): $66.81–$70.97 per share Direct holdings after sale: 267,174 shares +2 more

5 metrics

Shares sold 26,103 shares Total common shares sold on May 21, 2026

Sale price range (footnotes) $66.81–$70.97 per share Weighted average price ranges for reported sales

Direct holdings after sale 267,174 shares Direct BridgeBio common stock owned following transactions

Revocable trust holdings 4,358,447 shares Kumar Haldea Revocable Trust, with Neil Kumar as co-trustee

Family irrevocable trust holdings 555,686 shares Kumar Haldea Family Irrevocable Trust, with Neil Kumar as co-trustee

Key Terms

Rule 10b5-1 sales plan, weighted average sale price, beneficial ownership, Section 16

4 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."

weighted average sale price financial

"Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share."

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		S⁽¹⁾		2,256	D	$67.5687⁽²⁾	267,174	D
Common Stock	05/21/2026		S⁽¹⁾		6,725	D	$68.3025⁽³⁾	260,449	D
Common Stock	05/21/2026		S⁽¹⁾		5,072	D	$69.2235⁽⁴⁾	255,377	D
Common Stock	05/21/2026		S⁽¹⁾		11,250	D	$70.4814⁽⁵⁾	244,127	D
Common Stock	05/21/2026		S⁽¹⁾		800	D	$70.9189⁽⁶⁾	243,327	D
Common Stock								555,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽⁷⁾
Common Stock								4,358,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Remarks:

	/s/ Laura Woodhead, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many BridgeBio (BBIO) shares did CEO Neil Kumar sell on May 21, 2026?

Neil Kumar sold 26,103 shares of BridgeBio common stock on May 21, 2026. These were open-market sales reported across multiple Form 4 line items, all executed on the same date at different weighted average prices within specified price ranges.

At what prices did BridgeBio (BBIO) CEO Neil Kumar sell shares in this Form 4?

The reported sales occurred at weighted average prices corresponding to ranges from $66.81 to $70.97 per share. Individual transaction lines show specific prices such as $67.5687, $68.3025, $69.2235, $70.4814, and $70.9189 for different blocks of common stock sold.

How many BridgeBio (BBIO) shares does Neil Kumar hold after these transactions?

After the reported sales, Neil Kumar directly owns 267,174 BridgeBio common shares. Separate from this, a revocable trust and a family irrevocable trust associated with him hold 4,358,447 and 555,686 shares, respectively, as disclosed in the Form 4 ownership table and related footnotes.